More than anti-malarial agents: therapeutic potential of artemisinins in neurodegeneration

Bing-Wen Lu 1,2, Larry Baum 3,4,5, Kwok-Fai So 2,3,4, Kin Chiu 2,3,*, Li-Ke Xie 1,*
1 Department of Ophthalmology, Eye Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2 Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administration Region, China
3 State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong Special Administration Region, China
4 Center for Genomic Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong Special Administration Region, China
5 Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong Special Administration Region, China
6 GHM Institute of CNS Regeneration, Jinan University, Guangzhou, Guangdong Province, China

Funding: This work was supported by the Natural Science Foundation of Beijing of China, No. 7192235 (to LKX).

Abstract
Artemisinin, also called qinghaosu, is originally derived from the sweet wormwood plant (Artemisia annua), which is used in traditional Chinese medicine. Artemisinin and its derivatives (artemisinins) have been widely used for many years as anti-malarial agents, with few adverse side effects. Interestingly, evidence has recently shown that artemisinins might have a therapeutic value for several other diseases beyond malaria, including cancers, inflammatory diseases, and autoimmune disorders. Neurodegeneration is a challenging age-associated neurological disorder characterized by deterioration of neuronal structures as well as functions, whereas neuroinflammation has been considered to be an underlying factor in the development of various neurodegenerative disorders, including Alzheimer’s disease. Recently discovered properties of artemisinins suggested that they might be able to treat neurodegenerative disorders by decreasing oxidation, inflammation, and amyloid beta protein (Aβ). In this review, we will introduce artemisinins and highlight the possible mechanisms of their neuroprotective activities, suggesting that artemisinins might have therapeutic potential in neurodegenerative disorders.

Key Words: artemisinin; inflammation; neuroinflammation; neurodegeneration; Alzheimer’s disease; Parkinson’s disease; Aβ; anti-oxidation; neuroprotection; neural regeneration

Introduction
Artemisinin and its derivatives from the sweet wormwood plant (Artemisia annua, Asteraceae) are called artemisinins; they have been used in traditional Chinese medicine for a long time (Tu, 2011; Guo, 2016; Wong et al., 2017). The plant was first recognized by the Chinese physician Hong Ge (born in the year 283) for its fever-reducing property (Efferth, 2017). Youyou Tu, at the China Academy of Traditional Chinese Medicine, isolated artemisinin (Artemisinin structure research collaboration group, 1977; Tu, 2011; Guo, 2016) and tested it in clinical trials (Tu, 2016). Studies conducted in humans during 1980s–1990s led to the designation of artemisinins as a first-line treatment for malaria and helped Youyou Tu win the 2015 Nobel Prize in Physiology or Medicine (Chen, 2016). Artemisinin-based combination therapies have joined the currently established standard treatments of malarial parasites around the world (Qin et al., 2017). Interestingly, abundant evidence has recently accumulated demonstrating that artemisinins might also be useful for many other diseases beyond malaria, including cancers, inflammatory diseases, and autoimmune disorders (Raffetin et al., 2018).

Neurodegeneration is a type of neurological disorder that mainly occurs in the aging population and is characterized by deterioration of neuronal structures as well as functions (Kreiner, 2018). Neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease, are currently major challenges around the world (Olanow et al., 2009). The causes for neurodegenerative disorders are still not fully known, but might include excitotoxicity, oxidative stress, inflammation, and apoptosis (Alexander, 2017; Feldmann et al., 2019; Toosi et al., 2019). Signs of neuroinflammation have been proven in many AD mouse models before Aβ accumulation (Camara and De-Souza, 2018). Thus, neuroinflammation is now widely regarded as an important pathogenic factor of neurodegenerative disorders (Braidy and Grant, 2017; McCauley and Baloh, 2018; Niranjan, 2018).

Newly discovered properties of artemisinins suggest that they might be able to treat neurodegenerative diseases (Okorji et al., 2016; Zheng et al., 2016; Yan et al., 2017; Zeng et al., 2017). This review will explore this evidence.

A literature review was conducted in February 2019 using the PubMed. Using the key word “artemisinins”, 632 relevant publications published from 1956 to 2019 were retrieved. Among them, around 60 publications were examined using the key words “inflammation” OR “neuro-” OR “oxidation”.

*Correspondence to:
Li-Ke Xie, MD, bxielike@sina.com; Kin Chiu, PhD, datwai@hku.hk.

orcid: 0000-0001-6581-9007 (Kin Chiu)
0000-0001-5877-6459 (Bing-Wen Lu)

doi: 10.4103/1673-5374.255960

Received: December 29, 2018
Accepted: February 13, 2019
Chemical Structures and Pharmacological Actions of Artemisinins

It was Youyou Tu who first deduced the structure of artemisinin. Using mass spectroscopy, spectrophotometry and X-ray crystallography, she discovered that artemisinin is a sesquiterpene lactone endoperoxide (Tu, 2016). The clinically important artemisinins include artesunate, artemether, and dihydroartemisin (DHA) (Figure 1), which were discovered and developed in 1986 (Nair et al., 1986). Today, these derivatives are more commonly used than artemisinin itself to treat malaria because of the minimal adverse effects, as well as their better efficacy and tolerability (Pinheiro et al., 2018). Artesunate is the most important analog, displaying a more favorable pharmacological profile than artemisinin because of its greater water-solubility and higher oral bioavailability that enable it to act more rapidly (Pinheiro et al., 2018). Recently, novel artemisinin derivatives have also been designed. These are named SM, each with a specific number to identify it (Figure 2).

Neuroprotective Activity of Artemisinins

Artemisinins have been shown to have neuroprotective effects, and therefore they are potential candidates for the treatment of neurodegenerative disorders (Okorji et al., 2016; Zheng et al., 2016; Yan et al., 2017; Zeng et al., 2017). Other factors in their favor as potential treatments are their abilities to cross the blood-brain barrier as small lipophilic molecules and to protect against oxidative stress (Zheng et al., 2016).

Anti-oxidation

Artemisinin has been shown to have a neuroprotective effect on sodium nitroprusside-induced oxidative insult to PC12 cells and brain primary cortical neurons (Zheng et al., 2016). PC12 cells were pretreated with artemisinin of different concentrations (3.1–100 μM) before their exposure to sodium nitroprusside (800 μM). Cell viability was protected in a concentration-dependent manner with artemisinin pretreatment, as measured by MTT assay, caspase 3/7 activities, and by lactate dehydrogenase release. Extracellular signal-regulated kinases (ERK) is part of the mitogen-activated protein kinase (MAPK) family, one of the oldest families of serine/threonine protein kinases responsible for intracellular signaling (Bohush et al., 2018). Their results demonstrated that the ERK pathway could be activated by artemisinin (25 μM), as shown by western blot analysis, whereas PD98059, an ERK inhibitor, could block the protective effect displayed by artemisinin (Zheng et al., 2016).

Previous studies proposed dysfunctional cyclic-AMP response element binding protein (CREB) signaling in various mouse models of AD (Bartolotti et al., 2016; Etcheto et al., 2018). Many potential therapeutic approaches targeting CREB signaling have been studied for treatment of neurodegenerative disorders (Motaghinejad et al., 2017). Chong and Zheng (2016) demonstrated that artemisinin was able to suppress oxidative stress induced by hydrogen peroxide (H$_2$O$_2$) in D407 retinal pigment epithelial cells and that activation of ERK/CREB signaling was involved. Yan et al. (2017) demonstrated that artemisinin was able to protect retinal neuronal cells RGC-5 against oxidative insult induced by H$_2$O$_2$ via activation of the ERK1/2 pathway. Their flash electroretinogram results also interestingly found that, in a concentration-dependent manner, artemisinin injected intravitreally could protect retinal function damaged by light exposure.

Artemisinin has also been shown to protect neuronal HT-22 mouse hippocampal cells from glutamate-induced neuronal oxidative damage and cell death (Lin et al., 2018),...
with 25 μM producing the optimum protective effect. Their results further suggest that pretreatment of artemisinin could activate protein kinase B (Akt)/Bcl-2 signaling because MK2206, an Akt inhibitor, could block its protective effect.

Besides being linked with memory consolidation (Horwood et al., 2006), phosphoinositide 3-kinase/Akt (which artemisinins inhibit) is associated with a number of metabolic functions that are essential for neuronal viability but dysfunctional in AD (Cheng et al., 2011; De Felice, 2013). Moreover, mammalian target of rapamycin (mTOR) signaling is activated by Akt and strongly correlated with the presence of Aβ and tau protein that accumulate in AD (Caccamo et al., 2011). However, the role of mTOR in AD remains controversial because increased Aβ concentrations might increase mTOR signaling, but even higher Aβ concentrations can decrease mTOR signaling (Lafay-Chebassier et al., 2005).

Artesunate could mimic caloric restriction and extend lifespan in yeast (Wang et al., 2015). Downregulation of MAPK signaling was observed in their study, indicating a relationship between cytochrome c oxidase activation and artesunate-heme conjugation.

To sum up, the above results indicate that artemisinin may have neuroprotective effects against oxidative stress through modulating various signaling pathways, most importantly, the ERK, CREB, MAPK, and Akt/mTOR pathways.

**Anti-inflammation**

Suppression of inflammation is another effect of artemisinin derivatives. Because of the favorable pharmacological actions of artemisinins on various signaling pathways as well as their relatively safe properties, they have been recently studied in various models of inflammatory disorders (Shi et al., 2015; Tu, 2016).

Artemisinins have been demonstrated to suppress inflammatory responses through the suppression of many pro-inflammatory cytokines (Lin et al., 2016; Feng et al., 2017; Li et al., 2018; Lu et al., 2018; Qiang et al., 2018; Sun et al., 2018).

Nuclear factor kappa B (NF-κB) is involved in neurodegenerative disorders such as AD (He et al., 2018). Aβ neurotoxicity has been found to be closely linked to NF-κB activation (Bourne et al., 2007). Therefore, inhibiting NF-κB might treat neurodegenerative disorders (Kim et al., 2017; Subedi et al., 2017; Zhang and Xu, 2018). Another recent study showed that artemisinin B, an artemisinin derivative without a dioxygen bridge, could alleviate learning and memory impairment in AD through inhibiting neuro-inflammatory responses (Qiang et al., 2018). Both the in vivo and in vitro studies have demonstrated that artemisinin B might play its anti-neuroinflammatory role through regulating the toll-like receptor 4-myeloid differentiation factor 88/NF-κB pathway. In a mouse model of experimental cerebral ischemia/reperfusion injury, a water-soluble derivative of artemisinin, artesunate (10–40 mg/kg) was shown to attenuate inflammatory processes through activating nuclear factor erythroid 2-related factor 2 (Nrf2), which is an important transcription factor that activates anti-oxidation leading to neuroprotection, as well as through suppressing ROS-dependent p38 MARK (Lu et al., 2018).

Nrf2 activation and the up-regulation of antioxidant and anti-inflammatory genes have been suggested by a variety of studies to be attractive therapeutic targets to prevent neurodegenerative disorders (Abdalkader et al., 2018; Morroni et al., 2018). In a study of BV2 microglia, a lipid-soluble derivative of artemisinin, artemether, has been shown to induce Nrf2 activity via increasing its nuclear translocation as well as its binding to antioxidant response elements, suggesting a possible therapeutic neuroprotective effect (Okorji et al., 2016). Pretreatment by artemether (5–40 μM) was found to reduce, in a dose-dependent fashion, the production of nitrite as well as the expression of tumor necrosis factor-alpha, prostaglandin E2, and interleukin-6 in lipopolysaccharide-stimulated BV2 microglia co-cultured with HT22 neuronal cells. Also, their findings suggested that artemether might exert its anti-inflammatory effect through suppressing NF-κB and p38 MAPK signaling.

**Anti-Aβ**

Aβ peptide, which accumulates in AD, can be neurotoxic. Artemisinin can protect or rescue PC12 cells from cell death induced by a toxic fragment, Aβ 25–35 (Zeng et al., 2017). Treatment with 12.5 or 25 μM artemisinin for 1 hour reduced the death of PC12 cells after subsequent exposure to Aβ 25–35 for 24 hours. Reversing the order of exposure also reduces cell death, with 25 or 50 μM artemisinin for 24 hours rescuing PC12 cells that had been incubated with 0.1, 0.3, or 1 μM Aβ 25–35 for 30 minutes. Further study showed that low-concentration artemisinin might be able to promote neuronal differentiation of PC12 cells through activating the ERK1/2 and p38 MAPK signaling pathway (Sarina et al., 2013). These results suggest the potential application of artemisinin as a novel treatment of neurodegenerative disorders, especially AD.

**Challenges for Use of Artemisinins in Neurodegeneration**

Although artemisinin seems to be a pluripotent drug with possible clinical value in anti-malarial, anti-tumor, anti-inflammatory and anti-neurodegenerative roles, there are potential pitfalls (Yuan et al., 2017). In contrast to short-term high-dose artemisinin treatment against malaria, long-term treatment with low-dose artemisinin has generally been investigated for treatment of other diseases (Wang et al., 2015). However, long-term low-dose exposure to artemisinin might induce free radical scavengers that can destroy the vulnerable endoperoxide bridge structure within artemisinin (Sun and Zhou, 2017). Furthermore, unexpected metabolic dysfunctions or other abnormalities, including neurotoxicity, or genotoxicity due to sperm DNA damage, might also emerge upon excessive artemisinin use (Singh et al., 2015). Therefore, the effects of artemisinin on neurodegeneration, either positive or negative, should be assessed and thorough long-term toxicity testing is performed to ensure safety at the appropriate dose.
Prospect
In the words of the discoverer of artemisinin at the conclusion of her Nobel Lecture, “Expanding clinical applications of artesiminin is also of interest to public health. We know what it can do, we need to know why and how it does it, what else it can do, and how it can do better.” (Tu, 2016). Artesiminins have been demonstrated to alleviate neurodegeneration through reducing oxidation, inflammation, and Aβ toxicity, in both direct and indirect manners. However, research on artesiminins in neurodegenerative disorders is still limited, and much more will need to be studied. A better understanding of the neuroprotective activities of artesiminins might improve treatments of neurodegenerative disorders.

Author contributions: Manuscript writing: BWL; providing suggestions for the manuscript and manuscript revision: LB; discussions: KC, LKX, KFS; approval of final manuscript for publication: all authors.

Conflicts of interest: There are no conflicts of interest associated with this manuscript.

Financial support: This work was supported by the Natural Science Foundation of Beijing of China, No. 7192235 (to LKX). The funding body played no role in the manuscript preparation other than providing funding.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References
Abdalkader M, Lampinen R, Kanninen KM, Malm TM, Liddell JR (2018) Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Front Neurosci 12:466.

Alexander RW (2017) Use of PIXYL software analysis of brain MRI (with & without contrast) as valuable metric in clinical trial tracking in study of multiple sclerosis (MS) and related neurodegenerative processes. Clin Trials Degener Dis 2:1-6.

Artemisinin structure research collaboration group (1977) A new type of galacterepine lactone—artesiminin. Kexue Tongbao 22:142.

Bohus A, Niewiadomska G, Filipak A (2018) Role of mitogen activated protein kinase signaling in Parkinson's disease. Neuronal Regen Res 14(9):1494-1498. doi:10.4103/1673-5374.255960

Chen WJ (2016) Honoring antiparasitics: The 2015 Nobel Prize in Physiology or Medicine. Biomed J 39:93-97.

Cheng G, Ho WE, Goh FY, Guan SP, Kong LR, Lai WQ, Leung BP, Wong WS (2011) Anti-malarial drug artemunic attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PLoS One 6:e20932.

Chong CM, Zheng W (2016) Artemisinins protects human retinal pigment epithelium cells from hydrogen peroxide-induced oxidative damage through activation of ERK/CREB signaling. Redox Biol 9:50-56.

De Felice FG (2013) Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 123:531-539.

Efferth T (2017) Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib. Phytomedicine 37:58-61.

Etcheto M, Abad S, Petrov D, Pedros I, Busquets O, Sánchez-López E, Casadesús G, Beas-Zarate C, Carro E, Auladell C, Olloquequi J, Pallàs M, Folch J, Camins A (2018) Early preclinical changes in hippocampal CREB-binding protein expression in a mouse model of familial Alzheimer's disease. Mol Neurobiol 55:4885-4895.

Feldmann KG, Chowdhury A, Becker JL, McAlpin A, Ahmed T, Haider S, Richard Xia JX, Diaz K, Mehta MG, Mano I (2019) Non-canonical activation of CREB mediates neuroprotection in a Caenorhabditis elegans model of excitotoxic nesrosis. J Neurochem 148:531-549.

Feng X, Chen W, Xiao L, Gu F, Huang J, Taso BP, Sun L (2017) Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. Lupus 26:62-72.

Guo Z (2016) Artemisinin anti-malarial drugs in China. Acta Pharm Sin B 6:115-124.

He P, Yan S, Zheng J, Gao Y, Zhang S, Liu Z, Liu X, Xiao C (2018) Eriodictyol attenuates LPS-induced neuroinflammation, amyloidogenesis, and cognitive impairments via the inhibition of NF-kappaB in male C57BL/6j mice and BV2 microglial cells. J Agric Food Chem 66:10205-10214.

Horwood JM, Dufour F, Laroche S, Davis S (2006) Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 23:3375-3384.

Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, He PL, Zhang Y, Yang YF, Li Y, Tang W, Zuo JP (2009) SM934, a water-soluble derivative of artemisinin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol 9:1509-1517.

Kim MJ, Rehman SU, Amin FU, Kim MO (2017) Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Aβ1-42-induced neuroinflammation and neurodegeneration via the NF-kB/JNK/GSK3β signaling pathway. Nanomedicine 13:2533-2544.

Kreiner G (2018) What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium. Pharmacol Rep 70:1105-1115.

Lafay-Chébassier C, Pacclain M, Page G, Barc-Spain P, Perault-Pochat MC, Gil R, Pradier L, Hugon J (2005) mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem 94:215-225.

Li T, Zeng Q, Chen X, Wang G, Zhang H, Yu A, Wang H, Hu Y (2018) The therapeutic effect of artemusine on roacea through the inhibition of the JAK/STAT signaling pathway. Mol Med Rep 17:8385-8390.

Lin SP, Li W, Winters A, Liu R, Yang SH (2018) Artemisinin prevents glutamate-induced neuronal cell death via Akt pathway activation. Front Cell Neurosci 12:108.
Lin ZM, Yang XQ, Zhu FH, He SJ, Tang W, Zuo JP (2016) Artemisinin analogue SM934 attenuate collagen-induced arthritis by suppressing T follicular helper cells and T helper 17 cells. Sci Rep 6:38115.

Lu H, Wang B, Cui N, Zhang Y (2018) Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS dependent p38 MAPK and protects against cerebral ischemiareperfusion injury. Mol Med Rep 17:6639-6646.

McCauley ME, Baloh RH (2018) Inflammation in ALS/FTD pathogenesis. Acta Neuropathol doi: 10.1007/s00401-018-1933-9.

Morrone F, Sita G, Graziosi A, Turriini E, Finomogari C, Tarozzi A, Irelia P (2018) Neuroprotective effect of caffeic acid phenethyl ester in a mouse model of Alzheimer’s disease involves Nrf2/HO-1 pathway. Aging Dis 9:605-622.

Motagheinejad M, Motetvalian M, Fatima S, Faraji F, Mozaffari S (2017) The neuroprotective effect of curcumin against nicotine-induced neurotoxicity is mediated by CREB-BDNF signaling pathway. Neurochem Res 42:2921-2932.

Nair MS, Acton N, Klayman DL, Kendrick K, Basile DV, Mante S (1996) Production of artemisinin in tissue cultures of Artemisia annua. J Nat Prod 59:494-507.

Niranjan R (2018) Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration. Neurochem Int 120:13-20.

Okorji UP, Velagapudi R, El-Bakoush A, Fiebich BL, Olajide OA (2016) Antiinflammatory drug artemether inhibits neuroinflammation in BV2 microglia through Nrf2-dependent mechanisms. Mol Neurobiol 53:6426-6443.

Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72:S1-136.

Pinheiro LCS, Feitoso LM, Silveira FFD, Boechat N (2018) Current antimalarial therapies and advances in the development of semi-synthetic artemisinin derivatives. An Acad Bras Cienc 90:1251-1271.

Qiang W, Cai W, Yang Q, Yang L, Dai Y, Zhao Z, Yin J, Li Y, Li Q, Wang Y, Weng X, Zhang D, Chen Y, Zou X (2018) Artemisinin ameliorates immunosuppressive effects in vitro and in vivo. Acta Pharmacol Sin 39:511-518.

Qin Y, Yang G, Li M, Liu HJ, Zhong WL, Yan QX, Qiao KL, Yang JH, Zhai DH, Yang W, Chen S, Zhou HG, Sun T, Yang C (2017) Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway. Oncotarget 8:103815-103827.

Raffetin A, Bruneel F, Roussel C, Thellier M, Caumes E, Raffetin CL, Bruneel F, Roussel C, Thellier M, Buffet P, Caumes E, Raffetin CL (2016) Artemisinin mimics caloric restriction to extend yeast lifespan via a dual-phase mode: a conclusion drawn from global transcriptome profiling. Sci China Life Sci 58:451-465.

Wang JX, Tang W, Yang ZS, Wan J, Shi LP, Zhang Y, Zhou R, Ni J, Hou LF, Zhou Y, He PL, Yang YF, Li Y, Zuo JP (2007) Suppressing effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo. Eur J Pharmacol 564:211-218.

Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, Shen HM, Wang J (2017) Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action. Med Res Rev 37:1492-1517.

Yan F, Wang H, Gao Y, Xu J, Zheng W (2017) Artemisinin protects retinal neuronal cells against oxidative stress and restores retinal physiological function from light exposed damage. ACS Chem Neurosci 8:1713-1723.

Yuan DS, Chen YP, Tan LL, Huang SQ, Li CQ, Wang Q, Zeng QP (2017) Artemisinin: a panacea eligible for unrestricted use? Front Pharmacol 8:737.

Zeng Z, Xu J, Zheng W (2017) Artemisinin protects PC12 cells against beta-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol 12:625-633.

Zhang FX, Xu RS (2018) Juglalin ameliorates LPS-induced neuroinflammation in animal models of Parkinson’s disease and cell culture via inactivating TLR4/NF-kappaB pathway. Biomed Pharmacother 97:1011-1019.

Zhao YG, Wang Y, Guo Z, Gu AD, Dan HC, Baldwin AS, Hao W, Wan YY (2012) Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol 189:4417-4425.

Zheng W, Chong CM, Wang H, Zhou X, Zhang L, Wang R, Meng Q, Lazarovic M, Fang J (2016) Artemisinin conferred ERK mediated neuroprotection to PC12 cells and cortical neurons exposed to sodium nitroprusside-induced oxidative insult. Free Radic Biol Med 59:157-168.

Zhou WL, Wu JM, Wu QL, Wang JX, Zhou Y, Zhou R, He PL, Li XY, Yang YF, Zhang Y, Li Y, Zuo JP (2005) A novel artemisinin derivative, 3-(12-beta-artemisininoyl) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vitro and in vivo. Acta Pharmacol Sin 26:1352-1358.

C-Editor: Zhao M; S-Editors: Yu J, Li CH; L-Editor: Song LP; T-Editor: Jia Y